Reproductive biomedicine online · 2025
Impact of frozen embryo transfer on placenta accreta and institutional variations.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sugai Shunya, Tatsumi Takayuki, Ogawa Kohei, Nishijima Koji, Yoshihara Kosuke, Morisaki Naho
Аннотация
RESEARCH QUESTION: Does programmed cycle frozen embryo transfer (PC-FET) increase the risk of placenta accreta spectrum (PAS) compared with natural cycle FET (NC-FET), and does this risk vary according to facility-level utilization of PC-FET?
DESIGN: This nationwide, cross-sectional study analysed 38,973 frozen embryo transfer deliveries identified in the Japanese perinatal registry database (2020-2022), linked to the assisted reproductive technology registry database (2019-2022). The primary exposure was PC-FET versus NC-FET. Facilities were stratified into tertiles based on the proportion of PC-FET (low, medium and high). The primary outcome was PAS, defined as either clinical or pathological. Morbid PAS was defined as PAS accompanied by haemorrhage >2000 ml or managed with balloon tamponade, compression sutures, embolization, or peripartum hysterectomy. OR and 95% CI were estimated with stabilized inverse probability of treatment weighting and multivariable regression.
RESULTS: PAS occurred in 3.6% and 0.7% of PC-FET and NC-FET deliveries, respectively (OR 5.02, 95% CI 3.87-6.53). Morbid PAS occurred in 1.5% and 0.3% of PC-FET and NC-FET deliveries, respectively (OR 5.36, 95% CI 3.51-8.20). Facilities with a high proportion of PC-FET had a higher risk of PAS (OR 1.36, 95% CI 1.16-1.58) and morbid PAS (OR 1.34, 95% CI 1.07-1.70) compared with facilities with a low proportion of PC-FET.
CONCLUSIONS: This study provides robust evidence that PC-FET increases the risk of PAS. Further research should explore the association between facility variations and the incidence of PAS.
DESIGN: This nationwide, cross-sectional study analysed 38,973 frozen embryo transfer deliveries identified in the Japanese perinatal registry database (2020-2022), linked to the assisted reproductive technology registry database (2019-2022). The primary exposure was PC-FET versus NC-FET. Facilities were stratified into tertiles based on the proportion of PC-FET (low, medium and high). The primary outcome was PAS, defined as either clinical or pathological. Morbid PAS was defined as PAS accompanied by haemorrhage >2000 ml or managed with balloon tamponade, compression sutures, embolization, or peripartum hysterectomy. OR and 95% CI were estimated with stabilized inverse probability of treatment weighting and multivariable regression.
RESULTS: PAS occurred in 3.6% and 0.7% of PC-FET and NC-FET deliveries, respectively (OR 5.02, 95% CI 3.87-6.53). Morbid PAS occurred in 1.5% and 0.3% of PC-FET and NC-FET deliveries, respectively (OR 5.36, 95% CI 3.51-8.20). Facilities with a high proportion of PC-FET had a higher risk of PAS (OR 1.36, 95% CI 1.16-1.58) and morbid PAS (OR 1.34, 95% CI 1.07-1.70) compared with facilities with a low proportion of PC-FET.
CONCLUSIONS: This study provides robust evidence that PC-FET increases the risk of PAS. Further research should explore the association between facility variations and the incidence of PAS.